Last reviewed · How we verify
Meclofenamate
Meclofenamate is a Small molecule drug developed by Memorial Sloan Kettering Cancer Center. It is currently FDA-approved for Dysmenorrhea, Menorrhagia, Osteoarthritis.
At a glance
| Generic name | Meclofenamate |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Target | Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Dysmenorrhea
- Menorrhagia
- Osteoarthritis
- Pain
- Rheumatoid arthritis
Common side effects
- Diarrhea
- Nausea with or without vomiting
- Other gastrointestinal disorders
- Abdominal pain
- Pyrosis
- Flatulence
- Anorexia
- Constipation
- Stomatitis
- Peptic ulcer
- Edema
- Rash
Key clinical trials
- Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary (NA)
- Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meclofenamate CI brief — competitive landscape report
- Meclofenamate updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI
Frequently asked questions about Meclofenamate
What is Meclofenamate?
Meclofenamate is a Small molecule drug developed by Memorial Sloan Kettering Cancer Center, indicated for Dysmenorrhea, Menorrhagia, Osteoarthritis.
What is Meclofenamate used for?
Meclofenamate is indicated for Dysmenorrhea, Menorrhagia, Osteoarthritis, Pain, Rheumatoid arthritis.
Who makes Meclofenamate?
Meclofenamate is developed and marketed by Memorial Sloan Kettering Cancer Center (see full Memorial Sloan Kettering Cancer Center pipeline at /company/memorial-sloan-kettering-cancer-center).
What development phase is Meclofenamate in?
Meclofenamate is FDA-approved (marketed).
What are the side effects of Meclofenamate?
Common side effects of Meclofenamate include Diarrhea, Nausea with or without vomiting, Other gastrointestinal disorders, Abdominal pain, Pyrosis, Flatulence.
What does Meclofenamate target?
Meclofenamate targets Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3.
Related
- Target: All drugs targeting Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3
- Manufacturer: Memorial Sloan Kettering Cancer Center — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Dysmenorrhea
- Indication: Drugs for Menorrhagia
- Indication: Drugs for Osteoarthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing